GSK plc (NYSE:GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results